Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer?

Conditions

None listed

Brief summary

In this research project we will study quality of life issues related to having advanced ovarian cancer and undergoing chemotherapy. We are interested in knowing how women are doing during chemotherapy for ovarian cancer and whether symptom improvement occurs with treatment.

Felicia Roncolato, Rachel O’Connell, Luke Buizen, Florence Joly, Anne Lanceley et al. (19 authors)

Journal of Clinical Oncology2016-05-202 citations

10.1200/jco.2016.34.15_suppl.5508

Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥ 3 lines of chemotherapy (PPS ≥ 3)—The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).

Michael Friedländer, Martin R. Stockler, Rachel O’Connell, Florence Joly, Anne Lanceley et al. (17 authors)

Journal of Clinical Oncology2015-05-201 citations

10.1200/jco.2015.33.15_suppl.5536

Measuring subjective improvement of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/ GCIG/PoCoG).

Michael Friedländer, Martin R. Stockler, Phyllis Butow, Amit M. Oza, Rachel O’Connell et al. (10 authors)

Journal of Clinical Oncology2014-05-201 citations

10.1200/jco.2014.32.15_suppl.tps5615

Interventions

All patients will fill out a number of health realted quality of life (HRQL) questionnaires prior to, during, and after receiving palliative chemotherapy.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

*Age >= 18 years *Histologically confirmed ovarian cancer/primary peritoneal cancer * Recurrent / progressive disease measured by Cancer Antigen 125 (CA125), radiological or clinical) * Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-3 * Life Expectancy > 3 months * Able to commence treatment within 2 weeks of enrollment * Sufficient English to complete questionnaires independently in the stage 1 component which will be carried out in selected centers in Australia and New Zealand and Canada

Exclusion criteria

Any condition that compromises the patient’s ability to give informed consent.

Outcome results